were as susceptible to lysis by lysostaphin as methicillin-susceptible S. aureus controls were.
The staphylolytic enzyme lysostaphin was discovered by Schindler and Schuhardt (9) and was shown to lyse staphylococci but to be inactive against all other organisms (3, 6, 9). The basis for the specificity of lysostaphin appears to be its peptidolytic action on pentaglycine cross-linkages, which are peculiar to the cell walls of staphylococci (4). Schleifer and Kloos (10) proposed the use of lysostaphin susceptibility for differentiation of staphylococci from micrococci. Baker (1) found that most Staphylococcus aureus isolates tested were lysed by lysostaphin but that lysis of coagulase-negative staphylococci was inconsistent. Zygmunt et al. (15) found that over 400 strains of multiply resistant methicillinsusceptible S. aureus (MSSA) were lysèd by lysostaphin. Conversely, cross-resistance to seven antibiotics did not arise in laboratory-selected lysostaphin-resistant mutants. MSSA seems to be inherently susceptible to lysostaphin, but the literature is inconclusive on lysostaphin susceptibility of methicillin-resistant S. aureus (MRSA). Sabath et al. (8) reported diminished lysis but Seligman (11) reported enhanced lysis of MRSA by lysostaphin. Zygmunt et al. (14) reported that five strains initially isolated as MRSA were susceptible to lysostaphin but, on repeat testing, were found to have lost their methicillin resistance. No more than a dozen isolates were tested in any study, so no systematic study of the susceptibility of MRSA to lysostaphin has been reported. We 10-
